GlassScriptPhysician profile
Fatima Alao
NPI 1700047917
$3,760.37
in general payments reported to CMS, 2019-2025
45 companies · $650 in 2025
The $650 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $238 · 2021: $478 · 2022: $509 · 2023: $931 · 2024: $538 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,073 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,073.20 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,171.84 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $192.92 | 2019-2025 | |
| Ucb, INC. | $185.49 | 2019-2024 | Nayzilam, Briviact |
| Celgene Corporation | $184.14 | 2023 | Zeposia |
| Lilly USA, LLC | $132.58 | 2021-2025 | Kisunla, Reyvow, Emgality |
| Supernus Pharmaceuticals, INC. | $125.24 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $116.29 | 2019-2024 | Epidiolex |
| Alexion Pharmaceuticals, INC. | $108.38 | 2019-2023 | Soliris |
| Amgen INC. | $107.87 | 2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $106.86 | 2023 | Zeposia |
| Pfizer INC. | $104.59 | 2023-2025 | |
| Eisai INC. | $94.57 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $79.58 | 2025 | Inbrija, Xeomin |
| Avanir Pharmaceuticals, INC. | $76.38 | 2019-2022 | |
| Lundbeck LLC | $66.31 | 2024 | Vyepti |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatima Alao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.